Letters Response

Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4386 (Published 10 July 2013) Cite this as: BMJ 2013;347:f4386
  1. Alan Moses, global chief medical officer1
  1. 1Novo Nordisk, DK Denmark, 2880 Bagsvaerd, Denmark
  1. frrf{at}novonordisk.com

As a company with a 90 year history dedicated to diabetes care, research, and education, Novo Nordisk has always put patients first. We would like to respond and set out our position on the recent articles and related commentary on incretins and pancreatic damage.1

Firstly, regarding the safety profile of Victoza (liraglutide):

  • On the basis of an overall assessment of safety data from all available sources, including one of the largest clinical trial programmes within diabetes, and the clinical …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe